Logo of eidLink to Publisher's site
Emerg Infect Dis. 2000 Sep-Oct; 6(5): 458–465.
PMCID: PMC2627954

Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response.

Abstract

Toxin synthesis by Shiga toxin-producing Escherichia coli (STEC) appears to be coregulated through induction of the integrated bacteriophage that encodes the toxin gene. Phage production is linked to induction of the bacterial SOS response, a ubiquitous response to DNA damage. SOS-inducing antimicrobial agents, particularly the quinolones, trimethoprim, and furazolidone, were shown to induce toxin gene expression in studies of their effects on a reporter STEC strain carrying a chromosome-based stx2::lacZ transcriptional fusion. At antimicrobial levels above those required to inhibit bacterial replication, these agents are potent inducers (up to 140-fold) of the transcription of type 2 Shiga toxin genes (stx2); therefore, they should be avoided in treating patients with potential or confirmed STEC infections. Other agents (20 studied) and incubation conditions produced significant but less striking effects on stx2 transcription; positive and negative influences were observed. SOS-mediated induction of toxin synthesis also provides a mechanism that could exacerbate STEC infections and increase dissemination of stx genes. These features and the use of SOS-inducing antibiotics in clinical practice and animal husbandry may account for the recent emergence of STEC disease.

Full Text

The Full Text of this article is available as a PDF (145K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Karmali MA, Petric M, Lim C, Fleming PC, Steele BT. Escherichia coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic colitis. Lancet. 1983 Dec 3;2(8362):1299–1300. [PubMed]
  • Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargrett NT, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983 Mar 24;308(12):681–685. [PubMed]
  • Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet. 1998 Oct 10;352(9135):1207–1212. [PubMed]
  • Acheson DW. Nomenclature of enterotoxins. Lancet. 1998 Apr 4;351(9108):1003–1003. [PubMed]
  • Scotland SM, Willshaw GA, Smith HR, Rowe B. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol Infect. 1987 Dec;99(3):613–624. [PMC free article] [PubMed]
  • Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobayashi JM. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis. 1989 Dec;160(6):994–998. [PubMed]
  • Carter AO, Borczyk AA, Carlson JA, Harvey B, Hockin JC, Karmali MA, Krishnan C, Korn DA, Lior H. A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home. N Engl J Med. 1987 Dec 10;317(24):1496–1500. [PubMed]
  • Proulx F, Seidman E. Is antibiotic therapy of mice and humans useful in Escherichia coli O157:H7 enteritis? Eur J Clin Microbiol Infect Dis. 1999 Aug;18(8):533–534. [PubMed]
  • Mühldorfer I, Hacker J, Keusch GT, Acheson DW, Tschäpe H, Kane AV, Ritter A, Olschläger T, Donohue-Rolfe A. Regulation of the Shiga-like toxin II operon in Escherichia coli. Infect Immun. 1996 Feb;64(2):495–502. [PMC free article] [PubMed]
  • Neely MN, Friedman DI. Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. Mol Microbiol. 1998 Jun;28(6):1255–1267. [PubMed]
  • Kimmitt PT, Harwood CR, Barer MR. Induction of type 2 Shiga toxin synthesis in Escherichia coli O157 by 4-quinolones. Lancet. 1999 May 8;353(9164):1588–1589. [PubMed]
  • Matsushiro A, Sato K, Miyamoto H, Yamamura T, Honda T. Induction of prophages of enterohemorrhagic Escherichia coli O157:H7 with norfloxacin. J Bacteriol. 1999 Apr;181(7):2257–2260. [PMC free article] [PubMed]
  • Plunkett G, 3rd, Rose DJ, Durfee TJ, Blattner FR. Sequence of Shiga toxin 2 phage 933W from Escherichia coli O157:H7: Shiga toxin as a phage late-gene product. J Bacteriol. 1999 Mar;181(6):1767–1778. [PMC free article] [PubMed]
  • Fuchs S, Mühldorfer I, Donohue-Rolfe A, Kerényi M, Emödy L, Alexiev R, Nenkov P, Hacker J. Influence of RecA on in vivo virulence and Shiga toxin 2 production in Escherichia coli pathogens. Microb Pathog. 1999 Jul;27(1):13–23. [PubMed]
  • Yoh M, Frimpong EK, Honda T. Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunol Med Microbiol. 1997 Sep;19(1):57–64. [PubMed]
  • Grif K, Dierich MP, Karch H, Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):761–766. [PubMed]
  • Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377–392. [PMC free article] [PubMed]
  • Lewin CS, Amyes SG. The role of the SOS response in bacteria exposed to zidovudine or trimethoprim. J Med Microbiol. 1991 Jun;34(6):329–332. [PubMed]
  • Quillardet P, Hofnung M. The SOS chromotest: a review. Mutat Res. 1993 Oct;297(3):235–279. [PubMed]
  • Yee AJ, De Grandis S, Gyles CL. Mitomycin-induced synthesis of a Shiga-like toxin from enteropathogenic Escherichia coli H.I.8. Infect Immun. 1993 Oct;61(10):4510–4513. [PMC free article] [PubMed]
  • al-Jumaili I, Burke DA, Scotland SM, al-Mardini H, Record CO. A method of enhancing verocytotoxin production by Escherichia coli. FEMS Microbiol Lett. 1992 Jun 1;72(2):121–125. [PubMed]
  • Pavia AT, Nichols CR, Green DP, Tauxe RV, Mottice S, Greene KD, Wells JG, Siegler RL, Brewer ED, Hannon D, et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr. 1990 Apr;116(4):544–551. [PubMed]
  • Dundas S, Todd WT. Clinical presentation, complications and treatment of infection with verocytotoxin-producing Escherichia coli. Challenges for the clinician. Symp Ser Soc Appl Microbiol. 2000;(29):24S–30S. [PubMed]
  • Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000 Jun 29;342(26):1930–1936. [PMC free article] [PubMed]
  • Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, Arbus M, Woolley PV, Chiazze L, Schein PS, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989 Jun;7(6):781–789. [PubMed]
  • Takahashi K, Narita K, Kato Y, Sugiyama T, Koide N, Yoshida T, Yokochi T. Low-level release of Shiga-like toxin (verocytotoxin) and endotoxin from enterohemorrhagic Escherichia coli treated with imipenem. Antimicrob Agents Chemother. 1997 Oct;41(10):2295–2296. [PMC free article] [PubMed]
  • Cheetham BF, Katz ME. A role for bacteriophages in the evolution and transfer of bacterial virulence determinants. Mol Microbiol. 1995 Oct;18(2):201–208. [PubMed]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...